CP.TO 0.88VRT 8.93NVDA -0.07TSM 5.21JPM 2.67ZST.TO 0.01HSAV.TO -0.1HSUV.U.TO 0.01
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

101.95
-1.41 (1.36%)
as of Sep 11, 2026, 8:00:00 pm Market Open.
355 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 12, 2026, 12:00 am

This summary was created by AI, based on 13 opinions in the last 12 months.

Abbott Labs (ABT) has faced significant challenges over the past year, marked by declining stock performance and reduced growth expectations. While its recent acquisition aimed at expanding its cancer treatment portfolio is viewed positively, it is anticipated to take time before it becomes accretive to earnings. Analysts note that although growth has slowed and market share has been lost, the company's diagnostics and devices business shows signs of potential recovery. Despite these hurdles, many experts still consider ABT a high-quality name in the healthcare sector, highlighting its reasonable valuation compared to historic PE ratios and consistent dividend history. Overall, while caution is advised due to technical weaknesses and elevated competition, there remains an underlying belief in the stock's long-term viability.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
ALC,ABT
BUY

Abbott Labs(ABT)

Aug 31, 2011
Have grown earnings every single year since 1991. Only 10 or 11x earnings. Likes them in the health care space because they are diversified. Market is worried about their largest drug, whose patent expires in a few years. He doesn’t see it as a problem.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$21.27

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Aug 02, 2011
(A Top Pick July 26/10. Up 5.72%.) Diversified healthcare company. Branded drug division has Marot for arthritis etc., medical devices including stents and nutritional. Have also been making acquisitions in the branded generic space. Good diversity. About 20% of revenues come from emerging markets.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$50.20

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

Jul 08, 2011
He has a model price of $57.97, an 8% upside. Good company but he sees a lot of value elsewhere.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$53.33

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 24, 2011
Raised dividend 30+ years in a row. Is going to show 10% earnings growth over next 2-3 years. A good space. They got too cheap so there is an opportunity.
Photo of Barry SchwartzBarry SchwartzUnlock Rating
$53.33

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 03, 2011
All different types of health care services and products. 11 times this year’s earnings. Nice valuation and entry point here.
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$52.85

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

May 02, 2011
(A Top Pick April 26/10. Up 8.35%.) Have both generic and branded drug divisions. Making acquisitions to increase their emerging market exposure, which currently represent 25% of their revenues. Also has the number one share in the drug alluding stent business. Very strong nutritional business.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$52.59

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 27, 2011
Only a part of their business is in the pharma. Biggest drug is Humera for rheumatoid arthritis, which doesn’t go off patent until 2016. Also have a strong nutritional business. Earnings have grown every single year since 1991. Trades at about 11X earnings. Almost 4% dividend.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$52.18

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Mar 16, 2011
Likes it. Patent on Humera goes off in 2016. 20 years in a row they increased earnings per share. Reasonable multiple. They are not getting the benefit of the doubt for the good work they are doing internationally. The health care sector is out of favour. Steadily increase the dividend.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$46.71

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Abbott Labs(ABT)

Feb 02, 2011
Annual succession of increased earnings since 1992 but not getting credit for what they are doing. Trades at about 10X earnings. Health care has been a tough sector to be in. Be patient and let the sector come back into favour and let the street endorse what they are doing. Street is worried about expiration of their major drug Humera but that doesn’t expire until 2016.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$45.73

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Dec 15, 2010
(A Top Pick Jan 13/10. Down 10.82%.) Very consistent grower and still likes.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$48.12

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Nov 23, 2010
Recently checked back. Well managed and in good financial shape.
Photo of Don ReedDon Reed
Owned
Unlock Rating
$46.95

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Abbott Labs(ABT)

Nov 19, 2010
Good entry point at the support level of around $46. If it corrects and holds at $46, that is pretty powerful. Crummy relative strength, which is a pretty good sign. Do a partial Buy at $46 and another at around $43 and a final one at $41.
Photo of Hap (Robert) Sneddon FCSIHap (Robert) Sneddon FCSI
No
Unlock Rating
$47.40

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Jul 26, 2010
Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$49.24

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Abbott Labs(ABT)

May 27, 2010
The model price is $48.13, a 2% upside only. Fully priced.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$47.87

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

May 12, 2010
Have a little less than 50% of their business in pharmaceuticals. Their big drug is Humera for rheumatoid arthritis and doesn't come off patent until 2016. Also have about 20%-25% revenues from their nutritional business.
Photo of Gordon ReidGordon ReidUnlock Rating
$49.15

Stock price when the opinion was issued

$101.95

As of Sep 11, 2026. Market Open.

biotechnologypharmaceutical
Showing 196 to 210 of 223 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

KMB -0.33$98.15
XLV -0.3$165.36
META 3.65$648.03
DAL 1.67$79.91
ORCL -2.66$150.28

Today's Top Picks

CP.TO 0.88$123.84
VRT 8.93$257.06
NVDA -0.07$218.29
TSM 5.21$433.24
JPM 2.67$356.23

Popular Articles

Latest Sell Signals

ORCL -2.66$150.28
ORCL -2.66$150.28
URI 0.04$989.12
BBD.B.TO -4.9$300.82
BN.TO 0.29$52.93

Most Recent Experts

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

Greg Newman

Greg Newman

Scotia Wealth Management

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automatically

You may also like